Q1 2025 Earnings Forecast for Reviva Pharmaceuticals Holdings, Inc. Issued By HC Wainwright (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Reviva Pharmaceuticals in a research note issued on Monday, April 22nd. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.33) per share for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Reviva Pharmaceuticals’ Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.24) EPS and Q4 2025 earnings at ($0.21) EPS.

Separately, Benchmark reiterated a “speculative buy” rating and set a $17.00 price target on shares of Reviva Pharmaceuticals in a research report on Tuesday, April 16th.

Reviva Pharmaceuticals Stock Down 1.0 %

Shares of NASDAQ RVPH opened at $3.06 on Tuesday. The firm’s 50-day simple moving average is $3.60 and its 200 day simple moving average is $4.11. The company has a market cap of $85.44 million, a price-to-earnings ratio of -1.87 and a beta of -0.02. Reviva Pharmaceuticals has a 12-month low of $2.67 and a 12-month high of $9.25.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Armistice Capital LLC lifted its position in Reviva Pharmaceuticals by 194.0% during the 4th quarter. Armistice Capital LLC now owns 1,764,000 shares of the company’s stock valued at $9,085,000 after purchasing an additional 1,164,000 shares during the period. Vontobel Holding Ltd. acquired a new position in Reviva Pharmaceuticals during the 4th quarter valued at about $72,000. Finally, EMC Capital Management lifted its position in Reviva Pharmaceuticals by 1,294.3% during the 3rd quarter. EMC Capital Management now owns 123,915 shares of the company’s stock valued at $613,000 after purchasing an additional 115,028 shares during the period. 63.18% of the stock is currently owned by institutional investors and hedge funds.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.